Articles

Podcasts

Videos

Clinical

The former FDA commissioner weighs in on the best measures to mitigate skyrocketed new cases, and his timeline for national recovery.

Mark McLelland, MD, PhD: What We Need to Address COVID-19

Here is what you need to know about BNT162b2, possibly the first vaccine regulated for COVID-19 prevention.

Pfizer Submits COVID-19 Vaccine to FDA for Emergency Authorization

How Do the Pfizer and Moderna COVID-19 Vaccines Compare?

More than 13 million children did not receive their first DTP vaccine dose in 2019—and investigators anticipate the 2020 rate will be worse.

Fewer Infants in the Americas, Africa are Getting First-Year Vaccines

Data show none of the treated volunteers to develop COVID-19 experienced a severe form of the disease, versus 11 given placebo.

Moderna COVID-19 Vaccine mRNA-1273 Reports 94.5% Efficacy in Early Data

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.

Vaccine Race: The Pfizer Vaccine with William Schaffner, MD

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.

Moderna Could Have Preliminary COVID-19 Vaccine Data Soon

The company is still awaiting its threshold for total COVID-19 infections in its 44,000-patient assessment. Nonetheless, they believe they have made history.

Pfizer COVID-19 Vaccine Reports 90% Efficacy in Preliminary, Non-Reviewed Data

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

The Forgotten Infectious Disease Issues During COVID-19

Vaccination for VZV and HPV requires special consideration in immunocompromised patients. They are at risk for more severe viral illnesses if not immune, but they may also have decreased response to, and increased adverse effects from, vaccines.

PREVENTION